Addex Therapeutics (Switzerland) Insiders
| ADXN Stock | CHF 0.06 0.0002 0.35% |
Addex Therapeutics employs about 26 people. The company is managed by 7 executives with a total tenure of roughly 61 years, averaging almost 8.0 years of service per executive, having 3.71 employees per reported executive. Recap of Addex Therapeutics' management performance can provide insight into the venture performance.
| Timothy Dyer Insider CEO CoFounder |
| Werner Henrichi Insider Consultant |
Addex |
Addex Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.8786) % which means that it has lost $0.8786 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.0267) %, meaning that it generated substantial loss on money invested by shareholders. Addex Therapeutics' management efficiency ratios could be used to measure how well Addex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Addex Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Addex Therapeutics Price Series Summation is a cross summation of Addex Therapeutics price series and its benchmark/peer.
Addex Therapeutics Notable Stakeholders
An Addex Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Addex Therapeutics often face trade-offs trying to please all of them. Addex Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Addex Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Timothy Dyer | CEO CoFounder | Profile | |
| Werner Henrichi | Consultant | Profile | |
| Mikhail Kalinichev | Head Science | Profile | |
| JeanPhilippe Rocher | Head Chemistry | Profile | |
| Roger MD | Chief Director | Profile | |
| Lnaic Teyssdou | Head Fin | Profile | |
| Robert Lutjens | Head Biology | Profile |
About Addex Therapeutics Management Performance
The success or failure of an entity such as Addex Therapeutics often depends on how effective the management is. Addex Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Addex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Addex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Plan-les-Ouates, Switzerland. ADDEX N operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 17 people.
Please note, the imprecision that can be found in Addex Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Addex Therapeutics. Check Addex Therapeutics' Beneish M Score to see the likelihood of Addex Therapeutics' management manipulating its earnings.
Addex Therapeutics Workforce Analysis
Traditionally, organizations such as Addex Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Addex Therapeutics within its industry.Addex Therapeutics Manpower Efficiency
Return on Addex Therapeutics Manpower
| Revenue Per Employee | 112.2K | |
| Revenue Per Executive | 416.6K | |
| Net Loss Per Employee | 590.5K | |
| Net Loss Per Executive | 2.2M |
Additional Tools for Addex Stock Analysis
When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.